Continuing their discussion on the first patient profile, the expert panel focuses on the second-line treatment of patients with lower-risk MDS and symptomatic anemia.
Vanderbilt Symposium Highlights Recent Data on Novel Agents Under Evaluation in Hematologic Malignancies
Revisit the OncLive On Air Episodes From February 2024
CAR T-Cell Therapies Move Ahead in Pediatric and Adult ALL
FDA Approval Insights: Capivasertib Plus Fulvestrant in Advanced HR+/HER2- Breast Cancer With PIK3CA, AKT1, or PTEN Alterations
State of the Science Summit - Hematologic Malignancies: Chaired by Veronika Bachanova, MD, PhD, and Jeffrey Miller, MD
When Lung Cancer Took One Lung and COVID Took the Other, a Chicago Police Captain Was Left With Only One Option for Survival
Dr Pal Previews ASCO 2024 Data in Renal Cell Carcinoma
Prospective Data Reveal Most Young Survivors of Breast Cancer Could Successfully Give Birth
HPV Vaccinations Associated With Lower Rates of HPV-Caused Cancers in Patients Under 40 Years of Age
AI Virtual Navigation May Reengage Patients to Undergo Missed Colonoscopies